Last reviewed · How we verify
HEC73077 tablets — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HEC73077 tablets (HEC73077 tablets) — Sunshine Lake Pharma Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HEC73077 tablets TARGET | HEC73077 tablets | Sunshine Lake Pharma Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HEC73077 tablets CI watch — RSS
- HEC73077 tablets CI watch — Atom
- HEC73077 tablets CI watch — JSON
- HEC73077 tablets alone — RSS
Cite this brief
Drug Landscape (2026). HEC73077 tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/hec73077-tablets. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab